

Engineered toxin bodies targeting PD-L1 to alter tumor immunophenotypes and deliver broad antigenic diversity and patient coverage


Swati Khanna, Elizabeth Saputra, Wenzhao Dong, Lindsey Aschenbach, Lilia A. Rabia, Garrett L. Cornelison, Michaela Sousares, Jay Zhao, Lee Robinson, Betty Chang, Hilario J. Ramos, Joseph D. Dekker Molecular Templates Inc., Austin, TX



MT-6402 - potent ribosomal inhibition, Human and Cynomolgus PD-L1 binding, Reduced Checkpoint Blockade



MT-6402 elicits potent cytotoxicity on PD-L1 positive and clinically relevant tumor cell lines



Website: www.mtem.com; Contact: bd@mtem.com, joseph.dekker@mtem.com

Abstract 1628 AACR 2021

